Gufic Biosciences share price, P/E, ROE & financials

As of 6 Nov 2026, Gufic Biosciences trades at 58.8× trailing earnings, above the industry P/E of 28.7×. It earns ROCE of 15% and ROE of 10%, and sales grew 6.1% a year over 3 years while net profit fell 6.9%. Debt is 0.61× equity. It is a small-cap company with a market cap of ₹4,316 Cr, ranked 46th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 33% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹435.85
Day high: ₹438.90
Day low: ₹425.80
Prev. close: ₹434.45
Volume: 47.5K

Health check

1 good · 2 fair · 3 to check

ReturnsAhead
+32.9% over a year, better than 5 of 7 peers.
Price tagPricier
P/E 58.8 vs industry 28.7.
GrowthSlow
Sales +6.1%, profit −6.9% a year over 3 years.
ProfitabilityAverage
ROCE 14.8% vs peer median 17.9%.
Balance sheetFair
Debt 0.61× equity, interest covered 3.5×, Piotroski 4 of 9.
Red flags1 to check
P/E of 58.8 against an industry P/E of 28.7.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹4,316 Cr, #46 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹981 Cr · profit ₹73 Cr

Market cap: ₹4,316 Cr; Small cap
P/E: 58.8; Industry 28.7
Price to book: 6.49; Peers 4.99
Dividend yield: 0.02%
ROE: 10.1%; Peers 14.7%
ROCE: 14.8%; Peers 17.9%
Debt to equity: 0.61; Debt ₹405 Cr
EPS (TTM): ₹7.32; Face value ₹1
OPM (TTM): 16.8%; Net margin 7.5%
Sales growth: +16.6%; Latest quarter vs a year ago
Profit growth: +70.7%; Latest quarter vs a year ago
Price to sales: 4.40; EV/EBITDA 29.1

Strengths

Quarterly profit up 70.7% on a year ago.
Quarterly sales up 16.6% on a year ago.

Risks to check

P/E of 58.8 against an industry P/E of 28.7.

Derived automatically from reported figures. Not a recommendation.

About Gufic Biosciences

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal,…

Headquarters: Mumbai
Employees: 1,607
Sector: Healthcare
ISIN: INE742B01025
Website: gufic.com

Price range

52 weeks

₹268.00₹467.80

Today

₹425.80₹438.90

Avg volume (3M): 1.1 L
1-year return: plus 32.9%
From 52-week high: minus 8.0%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.87%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.30%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.81%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.59%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.93%	minus 6.6%
GUFICBIOGufic Biosciences	430.35	minus 0.94%	4,316	58.8	6.49	14.8%	10.1%	16.8%	6.1%	−6.9%	0.02%	plus 32.9%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.59%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
224	237	231	252	261
190	199	198	205	214
33.3	37.8	33	47.2	46.6
14.9%	16.0%	14.3%	18.7%	17.9%
0.9	2.1	0.8	−1.2	0.5
9.2	9.6	8.4	9.4	9.3
7.7	7.8	7.7	7.6	7.7
17.3	22.6	17.7	29	30
24.3%	25.6%	29.9%	24.4%	25.7%
13.1	16.8	12.4	21.9	22.3
1.30	1.68	1.24	2.18	2.22

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +6.1%
Profit CAGR 3Y: −6.9%
EPS CAGR 3Y: −8.0%
ROE: 10.1%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
680	770	746	813
–	+13.2%	minus 3.1%	+9.0%
542	620	607	661
138	150	138	151
20.2%	19.4%	18.6%	18.6%
−2	0.1	−0.3	1.2
6.6	14.8	23	35.2
22.3	17	21.1	30.8
0	−2.3	0.1	–
107	116	94.1	86.5
25.3%	25.5%	26.0%	25.8%
79.7	86.1	69.6	64.2
–	+8.1%	minus 19.1%	minus 7.8%
8.22	8.74	6.95	6.40

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
9.7	10	10	10
338	523	591	655
334	333	336	405
179	227	232	273
861	1,093	1,169	1,342
328	474	525	519
170	321	25	34
0.8	1.8	1.8	1.8
28.6	1.1	15.7	62.2
334	295	602	726
861	1,093	1,169	1,342

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−26.6	−7.5	123	45.1
−191	−102	−70.8	−31
234	82.4	−37.2	32.3
17	−27.5	14.6	46.5
−188	−113	−75.5	−31.2
−214	−120	47	14
−1	−1	−1	−1

Shareholding pattern

Source: NSE filings

72.5%

promoters

Promoters72.50%
Public27.50%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	72.50%	27.50%	0.00
30 Jun 2026	72.50%	27.50%	0.00
31 Mar 2026	72.50%	27.50%	0.00
31 Dec 2025	72.50%	27.50%	0.00
30 Sep 2025	72.50%	27.50%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you